Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Prices US IPO at $14 per Share

NEW YORK — Centogene said on Thursday that it has priced its planned US initial public offering of 4 million shares at $14 apiece for total gross proceeds of roughly $56 million.

The company has also granted the underwriters of the offering a 30-day option to purchase an additional 600,000 shares at the offering price, which would add another $8.4 million to the IPO's value.

SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering, with Baird and BTIG acting as co-managers. The stock is set to begin trading on the Nasdaq on Thursday under the ticker symbol CNTG.

Rostock, Germany-based Centogene offers rare disease genetic tests and services for clinical applications, as well as to support drug discovery and development programs for biopharma clients. The core of its business is its CentoMD database of clinically annotated genetic variants of rare diseases.

Last month, the company — which raised €25 million ($27.1 million) in Series A funding in 2017 — said it intends to use the proceeds of the IPO for R&D, working capital, and general corporate purposes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.